Contracts Management Branch, NICHD, National Institutes of Health, Executive Building, Suite 7A07, 6100 Executive Blvd MSC 7510, Bethesda, MD 20892-7510

A -- SYNTHESIS AND TESTING OF CONTRACEPTIVE AGENTS Contact Miss Virginia A. DeSeau, 301/496-4611/Contract Specialist, Paul J. Duska, 301/496-4611/Contracting Officer. The National Institute of Child Health and Human Development (NICHD) plans to continue in the preparation and development of contraceptive agents using recombinant DNA technology. The NICHD currently has a contract (NO1-HD-3-3177) with Washington University for the stated purpose. It is the intent of the NICHD to continue this project for one additional year with Washington University to address the following specific issues: (1) continued construction of scanning mutations in the alpha domains of hCG and FSH single chains, (2) testing of the biological activity of the mutants, and (3) determination of the stability of single chain hFSH, hLH and hCG. The Contractor will also establish large scale production of these chain forms. The determination to use other than full and open competition was made in accordance with 41 USC 253(c)(1), the FAR 5.207(c), and the FAR 6.302-1. The proposed source, by virtue of their prior work and availability of the necessary constructs, will continue this project without interruption. The purpose of this synopsis is to determine whether there are other sources with the requisite qualifications to perform the work described above. Capability statements should be brief and must be submitted within 45 days of the publication of this synopsis. See Note 22. (136)

Loren Data Corp. http://www.ld.com (SYN# 0006 19960517\A-0006.SOL)